Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Organisation › Details

Arsanis (Group)

Arsanis is a clinical-stage biotechnology company leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive therapy and treatment of serious infectious diseases. The company’s current programs address pathogenic processes selectively, aiming to preserve the healthy microbiome and potentially allowing Arsanis to address critical infections without contributing to the problem of resistance. The company is building a broad product pipeline addressing the most important infectious diseases that threaten patients globally. Its lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical study for the prevention of S. aureus pneumonia in high-risk patients. Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH). *


Period Start 2010-01-01 established
Products Industry ASN100 (Arsanis)
  Industry 2 anti-infective drug
Persons Person Russo, René (Arsanis 201702 CEO)
  Person 2 Nagy, Eszter (Arsanis 201010– CSO + Co-founder before SVP Research at Intercell AG)
Region Region Waltham, MA
  Country United States (USA)
  Street 890 Winter Street
Suite 230
  City 02451-1472 Waltham, MA
  Tel +1-781-819-5704
    Address record changed: 2020-12-02
Basic data Employees B: 11 to 50 (2013-10-17)
  Currency USD
  Cash 40,800,000 (2018-09-30)
    * Document for �About Section�: Arsanis, Inc.. (2/27/17). "Press Release: Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies". Waltham, MA & Vienna & Lebanon, NH.
Record changed: 2018-12-03


Picture [iito] Plain Stupid Simple 650x80px

More documents for Arsanis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px

» top